These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
1314 related items for PubMed ID: 16511379
21. Tetanus and pertussis vaccination coverage among adults aged ≥ 18 years --- United States, 1999 and 2008. Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep; 2010 Oct 15; 59(40):1302-6. PubMed ID: 20948508 [Abstract] [Full Text] [Related]
22. Decennial administration of a reduced antigen content diphtheria and tetanus toxoids and acellular pertussis vaccine in young adults. Mertsola J, Van Der Meeren O, He Q, Linko-Parvinen A, Ramakrishnan G, Mannermaa L, Soila M, Pulkkinen M, Jacquet JM. Clin Infect Dis; 2010 Sep 15; 51(6):656-62. PubMed ID: 20704493 [Abstract] [Full Text] [Related]
24. Reduced-antigen, combined diphtheria, tetanus and acellular pertussis vaccine, adsorbed (Boostrix®): a review of its properties and use as a single-dose booster immunization. McCormack PL. Drugs; 2012 Sep 10; 72(13):1765-91. PubMed ID: 22931522 [Abstract] [Full Text] [Related]
27. Immunogenicity and reactogenicity of a reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine as a single-dose booster in Singaporean adults. Chan SH, Tan PT, Han HH, Bock HL. Singapore Med J; 2006 Apr 10; 47(4):286-90. PubMed ID: 16572239 [Abstract] [Full Text] [Related]
30. Safety of repeated doses of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine in adults and adolescents. Jackson ML, Yu O, Nelson JC, Nordin JD, Tartof SY, Klein NP, Donahue JG, Irving SA, Glanz JM, McNeil MM, Jackson LA. Pharmacoepidemiol Drug Saf; 2018 Aug 10; 27(8):921-925. PubMed ID: 29862604 [Abstract] [Full Text] [Related]
34. Comparison of the safety and immunogenicity of concomitant and sequential administration of an adult formulation tetanus and diphtheria toxoids adsorbed combined with acellular pertussis (Tdap) vaccine and trivalent inactivated influenza vaccine in adults. McNeil SA, Noya F, Dionne M, Predy G, Meekison W, Ojah C, Ferro S, Mills EL, Langley JM, Halperin SA. Vaccine; 2007 Apr 30; 25(17):3464-74. PubMed ID: 17270320 [Abstract] [Full Text] [Related]
35. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010. Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep; 2011 Jan 14; 60(1):13-5. PubMed ID: 21228763 [Abstract] [Full Text] [Related]
36. Adverse events after tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine administered to adults 65 years of age and older reported to the Vaccine Adverse Event Reporting System (VAERS), 2005-2010. Moro PL, Yue X, Lewis P, Haber P, Broder K. Vaccine; 2011 Nov 21; 29(50):9404-8. PubMed ID: 21920404 [Abstract] [Full Text] [Related]
40. Humoral immunity 10 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine in the USA. Pool V, Tomovici A, Johnson DR, Greenberg DP, Decker MD. Vaccine; 2018 Apr 19; 36(17):2282-2287. PubMed ID: 29573876 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]